ArticleCancer discovery2021
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05054465 (A Phase 1b-2 Trial to Assess the Safety and Efficacy of a Venetoclax and Navitoclax Consolidation in High-risk Patients With T- Cell Acute Lymphoblastic Leukemia Prior to Allogeneic Transplantation Followed by Venetoclax and Navitoclax Post-transplant Maintenance), which is not on this map. Cited by 188 papers.
0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed
39.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1b-2 Trial to Assess the Safety and Efficacy of a Venetoclax and Navitoclax Consolidation in High-risk Patients With T- Cell Acute Lymphoblastic Leukemia Prior to Allogeneic Transplantation Followed by Venetoclax and Navitoclax Post-transplant Maintenance
Who cites it
188 citing papers in PubMed, 275 citations in OpenAlex.
- Trial
- A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.Blood advances · 2024Trial
- Understanding and clinical approach to early T-cell precursor acute lymphoblastic leukemia.Blood research · 2026Review
- Article
- Dynamic Switching of Apoptosis-Modulating Bim Heterodimers in Response to BH3 Mimetics in Xenograft Models of Hematologic Malignancies.Molecular cancer therapeutics · 2026Article
- Mitochondria as the Hub of Apoptosis: A Comprehensive Insight From Mitochondria to Interactions With Other Organelles.MedComm · 2026Review
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Functional profiling of ovarian cancer models reveals Bcl-xL/NOTCH targeting to overcome resistance.NPJ precision oncology · 2026Article
- Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells.Molecular metabolism · 2026Article
- Article
- Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Article
- Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.Nature communications · 2026Article
- β3-adrenergic blockade targets fatty acid oxidation to induce ferroptotic vulnerability in pediatric T-ALL.Biology direct · 2026Article
- Regulated cell death programs shaping cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Exploiting cellular senescence in hematologic malignancies.Translational oncology · 2026Review
- Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia.Leukemia · 2026Article
- Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reports.Annals of hematology · 2026Article
- Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL.Cell death & disease · 2026Article
- Correspondance: Venetoclax combined with FLAG-based chemotherapy induces rapid and deep responses in early T-cell precursor lymphoblastic leukemia/lymphoma. Report of two cases and review of the literature.Annals of hematology · 2026Article
128 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 15 institutions in 2 countries.
Vinod A PullarkatDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California. vpullarkat@coh.org.
Norman J LacayoDepartment of Pediatrics - Hematology/Oncology, Stanford University, Palo Alto, California.ORCID 0000-0003-4573-5118
Elias JabbourDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeffrey E RubnitzDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-9885-3527
Ashish BajelClinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.ORCID 0000-0002-3755-7334
Theodore W LaetschDepartment of Pediatrics, The University of Texas Southwestern Medical Center/Children's Health, Dallas, Texas.ORCID 0000-0002-8497-3138
Jessica LeonardDepartment of Hematology/Medical Oncology, Oregon Health Sciences University, Portland, Oregon.ORCID 0000-0001-5576-0048
Susan I ColacePediatrics - Hematology and Oncology, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0003-3868-3655
Seong Lin KhawRoyal Children's Hospital, Victoria, Australia.ORCID 0000-0002-9084-8974
Shaun A FlemingDepartment of Hematology, The Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.
Ryan J MattisonUniversity of Wisconsin Carbone Cancer Center, Madison, Wisconsin.
Robin NorrisDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Joseph T OpfermanDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Kathryn G RobertsDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7626-4043
Yaqi ZhaoDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-8230-5312
Chunxu QuDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Mohamed BadawiAbbVie Inc., North Chicago, Illinois.
Michelle SchmidtAbbVie Inc., North Chicago, Illinois.
Bo TongAbbVie Inc., North Chicago, Illinois.
John C PeskoAbbVie Inc., North Chicago, Illinois.
Yan SunAbbVie Inc., North Chicago, Illinois.
Jeremy A RossAbbVie Inc., North Chicago, Illinois.
Deeksha VishwamitraAbbVie Inc., North Chicago, Illinois.
Lindsey RosenwinkelAbbVie Inc., North Chicago, Illinois.
Su Young KimAbbVie Inc., North Chicago, Illinois.
Amanda JacobsonAbbVie Inc., North Chicago, Illinois.ORCID 0000-0002-5299-6204
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-1871-1850
Thomas B AlexanderDepartment of Pediatrics, The University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-0484-1574
Wendy StockThe University of Chicago Medicine, Chicago, Illinois.
AbbVie (United States) · USSt. Jude Children's Research Hospital · USChildren's Hospital of Philadelphia · USCincinnati Children's Hospital Medical Center · USCity of Hope · USNationwide Children's Hospital · USOregon Health & Science University · USPalo Alto University · USPeter MacCallum Cancer Centre · AURoyal Children's Hospital · AUThe Alfred Hospital · AUThe University of Texas MD Anderson Cancer Center · USUniversity of Chicago · USUniversity of North Carolina at Chapel Hill · USUniversity of Wisconsin Carbone Cancer Center · US
Funding
UNC Oncology K12K12CA120780 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WILLIAM Y. KIM · 2007 to 2026
$9.6MNCI NIH HHS K12 CA120780
Abstract
Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, a BCL-X
Indexed as
AdolescentAdultAgedAged, 80 and overAniline CompoundsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicChildDrug Therapy, CombinationFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrecursor Cell Lymphoblastic Leukemia-LymphomaAniline CompoundsAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicnavitoclaxSulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05054465ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.